Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: johansen js. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H, Høgdall EV, Johansen JS, Jørgensen M, Price PA, Engelholm SA, Høgdall CK. Dehn H, et al. Among authors: johansen js. Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93. doi: 10.1034/j.1600-0412.2003.00010.x. Acta Obstet Gynecol Scand. 2003. PMID: 12694127 Free article.
Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Johansen JS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202. doi: 10.1158/1055-9965.EPI-05-0011. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16492905 Review.
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. Svane IM, et al. Among authors: johansen js. Cancer Immunol Immunother. 2007 Sep;56(9):1485-99. doi: 10.1007/s00262-007-0293-4. Epub 2007 Feb 7. Cancer Immunol Immunother. 2007. PMID: 17285289 Free PMC article. Clinical Trial.
309 results